1. Serum glial fibrillary acidic protein is a predictor of brain metastases in patients with metastatic breast cancer
- Author
-
Caroline Mollevi, Nelly Ginestet, Amélie Darlix, William Jacot, Christophe Hirtz, Laurent Tiers, Sylvain Lehmann, Département d'oncologie Médicale, CRLCC Val d'Aurelle - Paul Lamarque, Institut de Génomique Fonctionnelle (IGF), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Institut du Cancer de Montpellier (ICM), Institut Desbrest de santé publique (IDESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), and CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)
- Subjects
MESH: Combined Modality Therapy ,Cancer Research ,glial fibrillary astrocytic protein ,Gastroenterology ,brain metastases ,MESH: Glial Fibrillary Acidic Protein ,Univariate analysis ,MESH: Middle Aged ,Glial fibrillary acidic protein ,biology ,Brain Neoplasms ,Area under the curve ,UCHL1 protein ,MESH: Follow-Up Studies ,Middle Aged ,Prognosis ,Combined Modality Therapy ,Metastatic breast cancer ,Survival Rate ,neurofilament light chain ,Oncology ,MESH: Brain Neoplasms ,Biomarker (medicine) ,Female ,MESH: Biomarkers, Tumor ,Adult ,medicine.medical_specialty ,MESH: Survival Rate ,Tau protein ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Breast Neoplasms ,tau protein ,MESH: Prognosis ,breast cancer ,Breast cancer ,Internal medicine ,Glial Fibrillary Acidic Protein ,Biomarkers, Tumor ,medicine ,Humans ,Retrospective Studies ,MESH: Humans ,Receiver operating characteristic ,business.industry ,MESH: Adult ,MESH: Retrospective Studies ,MESH: ROC Curve ,medicine.disease ,ROC Curve ,biology.protein ,business ,MESH: Female ,MESH: Breast Neoplasms ,Follow-Up Studies - Abstract
International audience; In patients with metastatic breast cancer (MBC), brain metastases (BM) are associated with high morbidity and mortality. However, there is no validated serum biomarker that accurately predicts BM occurrence in these patients, and the role of serum biomarkers for prognosis remains unclear. Here, we evaluated the association of neurofilament light chain (NfL), ubiquitin C-terminal hydrolase L1 (UCHL1), glial fibrillary acidic protein (GFAP) and tau serum levels with BM presence and prognosis in patients with MBC. In serum samples from patients with MBC with (n = 100) and without BM (n = 47), we measured the biomarker serum levels using single molecule array (Simoa) technology (Neurology-4-Plex assay). To evaluate their accuracy to identify patients with BM, we determined the receiver operating characteristic curve and the area under the curve (AUC) for each biomarker and calculated their sensitivity and specificity. The median serum levels of NfL, UCHL1, tau and GFAP were significantly higher in patients with BM. The AUC for GFAP (0.82, 95% confidence interval [CI] 0.75-0.88) was significantly higher than those of the other biomarkers considered independently. Using the medians as cutoff values, elevated serum levels of NfL, UCHL1, tau and GFAP were associated with BM in univariate analysis, but only high GFAP levels in multivariate analysis (odd ratio 23.4, 95% CI 6.8-80.5, P
- Published
- 2021
- Full Text
- View/download PDF